欧洲的微创结直肠癌手术:实施情况与结果
Minimally Invasive Colorectal Cancer Surgery in Europe: Implementation and Outcomes.
作者信息
Babaei Masoud, Balavarca Yesilda, Jansen Lina, Gondos Adam, Lemmens Valery, Sjövall Annika, Brge Johannesen Tom, Moreau Michel, Gabriel Liberale, Gonçalves Ana Filipa, Bento Maria José, van de Velde Tony, Kempfer Lana Raffaela, Becker Nikolaus, Ulrich Alexis, Ulrich Cornelia M, Schrotz-King Petra, Brenner Hermann
机构信息
From the Division of Clinical Epidemiology and Aging Research (MB, LJ, AG, HB), German Cancer Research Center (DKFZ); Division of Preventive Oncology (YB, CMU, PS-K, HB), German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany; Comprehensive Cancer Organization (VL), Utrecht, the Netherlands; Department of Molecular Medicine and Surgery (AS), Karolinska Institutet, Center for Digestive Diseases, Division of Coloproctology, Karolinska University Hospital, Stockholm, Sweden; Norwegian Cancer Registry (TBJ), Oslo, Norway; Datacenter (MM); Department of Surgical Oncology (LG), Institute Jules Bordet (IJB), Bruxelles, Belgium; Portuguese Oncology Institute of Porto (IPO-Porto) (AFG, MJB), Porto, Portugal; Biometrics Department (TvdV), The Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands; Clinical Cancer Registry (LRK, NB), National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ) ; Department of surgery of Heidelberg University Hospital (AU), Heidelberg, Germany; Huntsman Cancer Institute (CMU), Salt Lake City, UT; and German Cancer Consortium (DKTK) (HB), German Cancer Research Center (DKFZ), Heidelberg, Germany.
出版信息
Medicine (Baltimore). 2016 May;95(22):e3812. doi: 10.1097/MD.0000000000003812.
Minimally invasive surgery (MIS) of colorectal cancer (CRC) was first introduced over 20 years ago and recently has gained increasing acceptance and usage beyond clinical trials. However, data on dissemination of the method across countries and on long-term outcomes are still sparse.In the context of a European collaborative study, a total of 112,023 CRC cases from 3 population-based (N = 109,695) and 4 institute-based clinical cancer registries (N = 2328) were studied and compared on the utilization of MIS versus open surgery. Cox regression models were applied to study associations between surgery type and survival of patients from the population-based registries. The study considered adjustment for potential confounders.The percentage of CRC patients undergoing MIS differed substantially between centers and generally increased over time. MIS was significantly less often used in stage II to IV colon cancer compared with stage I in most centers. MIS tended to be less often used in older (70+) than in younger colon cancer patients. MIS tended to be more often used in women than in men with rectal cancer. MIS was associated with significantly reduced mortality among colon cancer patients in the Netherlands (hazard ratio [HR] 0.66, 95% confidence interval [CI] (0.63-0.69), Sweden (HR 0.68, 95% CI 0.60-0.76), and Norway (HR 0.73, 95% CI 0.67-0.79). Likewise, MIS was associated with reduced mortality of rectal cancer patients in the Netherlands (HR 0.74, 95% CI 0.68-0.80) and Sweden (HR 0.77, 95% CI 0.66-0.90).Utilization of MIS in CRC resection is increasing, but large variation between European countries and clinical centers prevails. Our results support association of MIS with substantially enhanced survival among colon cancer patients. Further studies controlling for selection bias and residual confounding are needed to establish role of MIS in survival of patients.
结直肠癌的微创手术(MIS)于20多年前首次引入,最近在临床试验之外越来越被接受和使用。然而,关于该方法在各国的传播情况以及长期结果的数据仍然稀少。在一项欧洲合作研究中,对来自3个基于人群的临床癌症登记处(N = 109,695)和4个基于机构的临床癌症登记处(N = 2328)的总共112,023例结直肠癌病例进行了研究,并比较了MIS与开放手术的使用情况。应用Cox回归模型研究基于人群的登记处中手术类型与患者生存之间的关联。该研究考虑了对潜在混杂因素的调整。接受MIS的结直肠癌患者百分比在各中心之间差异很大,并且总体上随时间增加。在大多数中心,与I期结肠癌相比,II至IV期结肠癌使用MIS的频率明显更低。老年(70岁以上)结肠癌患者使用MIS的频率往往低于年轻患者。直肠癌女性患者使用MIS的频率往往高于男性。在荷兰(风险比[HR] 0.66,95%置信区间[CI](0.63 - 0.69))、瑞典(HR 0.68,95% CI 0.60 - 0.76)和挪威(HR 0.73,95% CI 0.67 - 0.79),MIS与结肠癌患者死亡率显著降低相关。同样,在荷兰(HR 0.74,95% CI 0.68 - 0.80)和瑞典(HR 0.77,95% CI 0.66 - 0.90),MIS与直肠癌患者死亡率降低相关。结直肠癌切除术中MIS的使用正在增加,但欧洲国家和临床中心之间存在很大差异。我们的结果支持MIS与结肠癌患者生存率大幅提高之间的关联。需要进一步控制选择偏倚和残余混杂因素的研究来确定MIS在患者生存中的作用。